Management of residual disease after therapy for mediastinal germ cell tumor and normal serum markers

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Five to 10% of germ cell tumors originate in the anterior mediastinum. Fewer than 10-20% of anterior mediastinal masses are found to be primary mediastinal germ cell tumors, the majority consisting of thymic or thyroid pathologies or lymphomas. Germ cell tumors have three histologic categories: pure teratoma or pure seminoma with no other germ cell elements and nonseminomatous germ cell tumors. Sixty to 70% of all mediastinal germ cell tumors are teratomas, which are typically mature but occasionally demonstrate immature elements. Mature teratomas are almost always cured with surgical resection alone. Immature teratomas can grow more rapidly and also can degenerate into non-germ cell histologies, such as sarcomas and epithelial cancers, that are resistant to chemotherapy. Mediastinal seminomas have a high rate of cure with cisplatin-based chemotherapy alone. Unlike primary mediastinal nonseminomatous germ cell tumors (PMNSGCT), mediastinal seminomas have a prognosis similar to seminomas that originate in the testes or retroperitoneum.1 The vast majority of residual masses following chemotherapy for mediastinal seminoma represent complete tumor necrosis without viable neoplasm. Seminomas are therefore classified as favorable prognosis germ cell tumors.

Original languageEnglish (US)
Title of host publicationDifficult Decisions in Thoracic Surgery (Second Edition)
Subtitle of host publicationAn Evidence-Based Approach
PublisherSpringer London
Pages445-452
Number of pages8
ISBN (Print)9781849963640
DOIs
StatePublished - Dec 1 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Management of residual disease after therapy for mediastinal germ cell tumor and normal serum markers'. Together they form a unique fingerprint.

  • Cite this

    Riggs, H. D., Einhorn, L. H., & Kesler, K. A. (2011). Management of residual disease after therapy for mediastinal germ cell tumor and normal serum markers. In Difficult Decisions in Thoracic Surgery (Second Edition): An Evidence-Based Approach (pp. 445-452). Springer London. https://doi.org/10.1007/978-1-84996-492-0_52